Cited by 63Drug Transport and Resistance MechanismsMetabolism, Diabetes, and CancerCholesterol and Lipid Metabolism

The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis

Open access
Ploton, Maheul, Mazuy, Claire, Gheeraert, Céline, Dubois, Vanessa, Berthier, Alexandre, Dubois-Chevalier, Julie, Maréchal, Xavier, Bantubungi, Kadiombo +7 more·2018·Journal of Hepatology

Abstract

BACKGROUND & AIMS: Embedded into a complex signaling network that coordinates glucose uptake, usage and production, the nuclear bile acid receptor FXR is expressed in several glucose-processing organs including the liver. Hepatic gluconeogenesis is controlled through allosteric regulation of gluconeogenic enzymes and by glucagon/cAMP-dependent transcriptional regulatory pathways. We aimed to elucidate the role of FXR in the regulation of fasting hepatic gluconeogenesis. METHODS: The role of FXR in hepatic gluconeogenesis was assessed in vivo and in mouse primary hepatocytes. Gene expression patterns in response to glucagon and FXR agonists were characterized by quantitative reverse transcription PCR and microarray analysis. FXR phosphorylation by protein kinase A was determined by mass spectrometry. The interaction of FOXA2 with FXR was identified by cistromic approaches and in vitro protein-protein interaction assays. The functional impact of the crosstalk between FXR, the PKA and FOXA2 signaling pathways was assessed by site-directed mutagenesis, transactivation assays and restoration of FXR expression in FXR-deficient hepatocytes in which gene expression and glucose production were assessed. RESULTS: FXR positively regulates hepatic glucose production through two regulatory arms, the first one involving protein kinase A-mediated phosphorylation of FXR, which allowed for the synergistic activation of gluconeogenic genes by glucagon, agonist-activated FXR and CREB. The second arm involves the inhibition of FXR's ability to induce the anti-gluconeogenic nuclear receptor SHP by the glucagon-activated FOXA2 transcription factor, which physically interacts with FXR. Additionally, knockdown of Foxa2 did not alter glucagon-induced and FXR agonist enhanced expression of gluconeogenic genes, suggesting that the PKA and FOXA2 pathways regulate distinct subsets of FXR responsive genes. CONCLUSIONS: Thus, hepatic glucose production is regulated during physiological fasting by FXR, which integrates the glucagon/cAMP signal and the FOXA2 signal, by being post-translationally modified, and by engaging in protein-protein interactions, respectively. LAY SUMMARY: Activation of the nuclear bile acid receptor FXR regulates gene expression networks, controlling lipid, cholesterol and glucose metabolism, which are mostly effective after eating. Whether FXR exerts critical functions during fasting is unknown. The results of this study show that FXR transcriptional activity is regulated by the glucagon/protein kinase A and the FOXA2 signaling pathways, which act on FXR through phosphorylation and protein-protein interactions, respectively, to increase hepatic glucose synthesis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2018.06.022

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • T3 treatment does not prevent the loss of Hep-ID TF gene expression that occurs spontaneously when primary mouse hepatocytes are cultured in vitro.

    “We could not however observe any protective role for T3 treatment with regards to the loss of Hep‐ID TF gene expression spontaneously occurring when primary mouse hepatocytes (MPH) are cultured in vitro (Ploton et al, 2018; Seirup et al, 2022; Appendix Fig S14).”

    From An extended transcription factor regulatory network controls hepatocyte identity (2023) · cites this paper as Ploton et al, 2018

    The Mice strains and experimentation and Glucose production sections describe primary mouse hepatocyte isolation and culture, but do not report a spontaneous loss of hepatocyte-identity transcription-factor expression. Searches for T3, thyroid hormone, and culture-related loss of transcription-factor expression found no passage assessing whether T3 prevents that loss. The citing sentence presents the T3 observation as the citing authors’ own result, but our copy also does not establish the background loss attributed to Ploton et al. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 54

  1. Rui L. Energy metabolism in the liver. Compr Physiol 2014;4:177-197.
  2. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010;27:136-142.
  3. Soty M, Gautier-Stein A, Rajas F, Mithieux G. Gut-brain glucose signaling in energy homeostasis. Cell Metab 2017;25:1231-1242.
  4. Sharabi K, Tavares CD, Rines AK, Puigserver P. Molecular pathophysiol- ogy of hepatic glucose production. Mol Aspects Med 2015;46:21-33.
  5. Karagianni P, Talianidis I. Transcription factor networks regulating hepatic fatty acid metabolism. Biochim Biophys Acta 2015;1851:2-8.
  6. Oosterveer MH, Schoonjans K. Hepatic glucose sensing and integrative pathways in the liver. Cell Mol Life Sci 2014;71:1453-1467.
  7. Pilkis SJ, Granner DK. Molecular physiology of the regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Physiol 1992;54:885-909.
  8. El-Maghrabi MR, Lange AJ, Kummel L, Pilkis SJ. The rat fructose-1,6- bisphosphatase gene. Structure and regulation of expression. J Biol Chem 1991;266:2115-2120.
  9. Hutton JC, O'Brien RM. Glucose-6-phosphatase catalytic subunit gene family. J Biol Chem 2009;284:29241-29245.
  10. Shen N, Jiang S, Lu JM, Yu X, Lai SS, Zhang JZ, et al. The constitutive activation of Egr-1/C/EBPa mediates the development of type 2 diabetes mellitus by enhancing hepatic gluconeogenesis. Am J Pathol 2015;185:513-523.
  11. Rines AK, Sharabi K, Tavares CD, Puigserver P. Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nat Rev Drug Discov 2016;15:786-804.
  12. Mazuy C, Helleboid A, Staels B, Lefebvre P. Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci 2015;72:1631-1650.
  13. Prawitt J, Abdelkarim M, Stroeve JH, Popescu I, Duez H, Velagapudi VR, et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011;60:1861-1871.
  14. Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat Commun 2015;6:7629.
  15. Duran-Sandoval D, Cariou B, Percevault F, Hennuyer N, Grefhorst A, van Dijk TH, et al. The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition. J Biol Chem 2005;280:29971-29979.
  16. Caron S, Huaman SC, Dehondt H, Ploton M, Briand O, Lien F, et al. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. Mol Cell Biol 2013;33:2202-2211.
  17. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006;103:1006-1011.
  18. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010;51:771-784.
  19. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006;116:1102-1109.
  20. Jin L, Feng X, Rong H, Pan Z, Inaba Y, Qiu L, et al. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. Nat Commun 2013;4:1937.
  21. Ma Y, Huang Y, Yan L, Gao M, Liu D. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res 2013;30:1447-1457.
  22. Park MJ, Kong HJ, Kim HY, Kim HH, Kim JH, Cheong JH. Transcriptional repression of the gluconeogenic gene PEPCK by the orphan nuclear receptor SHP through inhibitory interaction with C/EBPalpha. Biochem J 2007;402:567-574.
  23. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 2004;279:23158-23165.
  24. Cariou B, Bouchaert E, Abdelkarim M, Dumont J, Caron S, Fruchart JC, et al. FXR-deficiency confers increased susceptibility to torpor. FEBS Lett 2007;581:5191-5198.
  25. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk T, Grefhorst A, Bouchaert E, et al. Transient impairment of the adaptive response to fasting in FXR-deficient mice. FEBS Lett 2005;579:4076-4080.
  26. Cariou B, van HK, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006;281:11039-11049.
  27. Renga B, Mencarelli A, D'Amore C, Cipriani S, Baldelli F, Zampella A, et al. Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition. FASEB J 2012;26:3021-3031.
  28. Porez G, Gross B, Prawitt J, Gheeraert C, Berrabah W, Alexandre J, et al. The hepatic orosomucoid/alpha1-acid glycoprotein gene cluster is regulated by the nuclear bile acid receptor FXR. Endocrinology 2013;154:3690-3701.
  29. Sinai CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000;102:731-744.
  30. Berrabah W, Aumercier P, Gheeraert C, Dehondt H, Bouchaert E, Alexandre J, et al. Glucose sensing O-GlcNAcylation pathway regulates the nuclear bile acid receptor farnesoid X receptor (FXR). Hepatology 2014;59:2022-2033.
  31. Lien F, Berthier A, Bouchaert E, Gheeraert C, Alexandre J, Porez G, et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J Clin Invest 2014;124:1037-1051.
  32. Gineste R, Sirvent A, Paumelle R, Helleboid S, Aquilina A, Darteil R, et al. Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol Endocrinol 2008;22:2433-2447.
  33. Fang XJ, Yu SX, Lu YL, Bast RC, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA 2000;97:11960-11965.
  34. Thomas AM, Hart SN, Kong B, Fang J, Zhong XB, Guo GL. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 2010;51:1410-1419.
  35. Everett LJ, Le LJ, Lukovac S, Bernstein D, Steger DJ, Lazar MA, et al. Integrative genomic analysis of CREB defines a critical role for tran- scription factor networks in mediating the fed/fasted switch in liver. BMC Genomics 2013;14:337.
  36. The Encode Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012;489:57-74.
  37. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995;81:687-693.
  38. Howell JJ, Stoffel M. Nuclear export-independent inhibition of Foxa2 by insulin. J Biol Chem 2009;284:24816-24824.
  39. Wolfrum C, Besser D, Luca E, Stoffel M. Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phos- phorylation and nuclear/cytosolic localization. Proc Natl Acad Sci USA 2003;100:11624-11629.
  40. Bochkis IM, Schug J, Rubins NE, Chopra AR, O'Malley BW, Kaestner KH. Foxa2-dependent hepatic gene regulatory networks depend on physio- logical state. Physiol Genomics 2009;38:186-195.
  41. Soccio RE, Tuteja G, Everett LJ, Li Z, Lazar MA, Kaestner KH. Species- specific strategies underlying conserved functions of metabolic tran- scription factors. Mol Endocrinol 2011;25:694-706.
  42. Sekiya T, Muthurajan UM, Luger K, Tulin AV, Zaret KS. Nucleosome- binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA. Genes Dev 2009;23:804-809.
  43. Chavez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology 2017;152:e1673.
  44. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005;146:984-991.
  45. Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, Arita E, et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expendi- ture. J Biol Chem 2011;286:26913-26920.
  46. Garcia-Rodriguez JL, Barbier-Torres L, Fernandez-Alvarez S, Gutierrez-de JV, Monte MJ, Halilbasic E, et al. SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mam- malian target of rapamycin signaling. Hepatology 2014;59:1972-1983.
  47. Wang J, Mauvoisin D, Martin E, Atger F, Galindo AN, Dayon L, et al. Nuclear proteomics uncovers diurnal regulatory landscapes in mouse liver. Cell Metab 2017;25:102-117.
  48. Robles MS, Humphrey SJ, Mann M. Phosphorylation is a central mechanism for circadian control of metabolism and physiology. Cell Metab 2017;25:118-127.
  49. Dubois-Chevalier J, Dubois V, Dehondt H, Mazrooei P, Mazuy C, Serandour AA, et al. The logic of transcriptional regulator recruitment architecture at cis-regulatory modules controlling liver functions. Genome Res 2017;27:985-996.
  50. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89:147-191.
  51. Zhang Y, Hagedorn CH, Wang L. Role of nuclear receptor SHP in metabolism and cancer. Biochim Biophys Acta 2011;1812:893-908.
  52. Kim JY, Kim HJ, Kim KT, Park YY, Seong HA, Park KC, et al. Orphan nuclear receptor small heterodimer partner represses hepatocyte nuclear factor 3/Foxa transactivation via inhibition of its DNA binding. Mol Endocrinol 2004;18:2880-2894.
  53. von Meyenn F, Porstmann T, Gasser E, Selevsek N, Schmidt A, Aebersold R, et al. Glucagon-induced acetylation of Foxa2 regulates hepatic lipid metabolism. Cell Metab 2013;17:436-447.
  54. Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M. Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 2004 Dec 23;432:1027-1032.

Cited by

Sorted by citations

Authors
Ploton, M., Mazuy, C., Gheeraert, C., Dubois, V., Berthier, A., Dubois-Chevalier, J., Maréchal, X., Bantubungi, K., Diemer, H., Cianférani, S., Strub, J.-M., Helleboid-Chapman, A., Eeckhoute, J., Staels, B., & Lefebvre, P.
Affiliations
  • Inserm (FR)
  • Centre National de la Recherche Scientifique (FR)
Corresponding author
Staels, Bart
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2018-11
Volume
69
Issue
5
Pages
1099-1109
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2870279711
Cited by
63
References
2
Citations by year
2026: 7 · 2025: 10 · 2024: 4 · 2023: 9 · 2022: 11 · 2021: 13 · 2020: 5 · 2019: 4
FWCI
2.07
Type
journal article
Language
en
Open access
Locations
  • Journal of Hepatology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by-nc-nd)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • HAL (submittedVersion, other-oa)
  • LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
Funders
  • Fondation pour la Recherche Médicale (DEQ20150331724)
  • Inserm
  • University of Lille
  • Agence Nationale pour la Recherche (ANR-10-LBEX-46, ANR-10-INBS-08)
  • French Ministry of Research
  • Advanced ERC Grant (694717)
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
hepatic gluconeogenesis, protein kinase A, FOXA2, glucagon signaling, CREB, protein-protein interaction, gluconeogenic gene expression, hepatocytes, glucose metabolism regulation, cAMP signaling, transcriptional regulation, post-translational modification
MeSH terms
Receptor, Farnesoid X-Activated, Animals, Fasting, Gene Expression Regulation, Glucagon, Gluconeogenesis, Glucose, Liver, Male, Mice, Inbred C57BL, Phosphorylation, Cyclic AMP-Dependent Protein Kinases, Receptors, Cytoplasmic and Nuclear, Hepatocytes, Mice, Hepatocyte Nuclear Factor 3-beta

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review